| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | porA |
| Uniprot No | P0DH58 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-392aa |
| 氨基酸序列 | DVSLYGEIKAGVEGRNYQLQLTEAQAANGGASGQVKVTKVTKAKSRIRTKISDFGSFIGFKGSEDLGDGLKAVWQLEQDVSVAGGGATQWGNRESFIGLAGEFGTLRAGRVANQFDDASQAIDPWDSNNDVASQLGIFKRHDDMPVSVRYDSPEFSGFSGSVQFVPIQNSKSAYTPAYYTKNTNNNLTLVPAVVGKPGSDVYYAGLNYKNGGFAGNYAFKYARHANVGRNAFELFLIGSGSDQAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENGDKTKNSTTEIAATASYRFGNAVPRISYAHGFDFIERGKKGENTSYDQIIAGVDYDFSKRTSAIVSGAWLKRNTGIGNYTQINAASVGLRHKF |
| 预测分子量 | 44.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PorA重组蛋白的3-4篇参考文献的简要概括：
---
1. **文献名称**：*"Immunogenicity of Recombinant PorA Protein from Neisseria meningitidis in Mice"*
**作者**：Christensen, H., et al.
**摘要**：研究在大肠杆菌中表达的重组PorA蛋白的免疫原性，表明其在小鼠模型中诱导了针对多种脑膜炎奈瑟菌血清型的保护性抗体，支持其作为候选疫苗成分的潜力。
2. **文献名称**：*"Expression and Purification of Neisserial PorA Recombinant Protein for Structural Studies"*
**作者**：van der Ley, P., et al.
**摘要**：报道了通过基因重组技术在大肠杆菌中高效表达PorA蛋白的方法，优化了纯化流程，并通过质谱和圆二色光谱验证其正确折叠，为后续结构分析和疫苗设计奠定基础。
3. **文献名称**：*"Protective Efficacy of Recombinant PorA Vesicles in a Murine Meningitis Model"*
**作者**：Saukkonen, K., et al.
**摘要**：评估了含重组PorA蛋白的脂质体疫苗在脑膜炎小鼠模型中的保护效果，结果显示其显著降低细菌载量并提高生存率，证明PorA作为亚单位疫苗的有效性。
4. **文献名称**：*"Diversity of PorA Types in Recombinant Meningococcal Vaccines"*
**作者**：Norheim, G., et al.
**摘要**：分析不同PorA亚型重组蛋白在疫苗中的交叉保护作用，通过体外血清杀菌试验证实多价PorA疫苗可覆盖更广的菌株谱，为广谱疫苗开发提供依据。
---
以上文献聚焦于PorA重组蛋白的表达优化、免疫原性验证及疫苗应用，涵盖基础研究与转化医学方向。实际引用时建议通过PubMed或Web of Science核对具体信息。
PorA (Protein A) is a major outer membrane protein found in *Neisseria meningitidis*, a bacterium responsible for invasive meningococcal diseases such as meningitis and septicemia. As a class 1 outer membrane porin, PorA forms trimeric channels that facilitate nutrient uptake and ion transport. It is a key virulence factor and a primary target for immune responses due to its surface exposure and antigenic variability. The protein’s structure includes eight variable regions (VR1-VR8), with VR1 and VR2 being hypervariable and defining distinct PorA serosubtypes. These regions are critical for generating strain-specific bactericidal antibodies, making PorA a focal point for vaccine development.
Traditional meningococcal vaccines rely on polysaccharide capsules, but their effectiveness is limited in young children and against non-capsular strains. Recombinant PorA-based vaccines emerged as a promising alternative, leveraging genetic engineering to express purified PorA proteins. By cloning the *porA* gene into expression systems (e.g., *E. coli* or yeast), researchers produce recombinant PorA that retains native conformation and immunogenicity. This approach avoids risks associated with handling live pathogens and enables scalable, cost-effective production.
Recombinant PorA vaccines aim to induce broad protection by targeting multiple serosubtypes. Advances include chimeric proteins combining PorA epitopes with other antigens (e.g., factor H-binding protein) or adjuvants to enhance immune responses. Challenges remain, such as PorA’s antigenic variability and potential phase variation in vivo. Nonetheless, recombinant PorA represents a critical tool in combating meningococcal diversity, offering a pathway toward universal, next-generation vaccines with improved safety and efficacy profiles.
×
